PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), a leading specialty finance company providing debt and equity growth capital to venture capital and private equity backed technology and life science companies, announced today that it has completed the sale of common stock acquired upon exercise of a warrant for shares of Omrix Biopharmaceuticals, Inc. (NASD:OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products. The sale of the common stock was completed during November 2006 and, accordingly, Hercules received gross proceeds of approximately $743,000, representing an IRR in excess of 30% on the total investment.
